Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NWV4

UPID:
CZIB_HUMAN

ALTERNATIVE NAMES:
UPF0587 protein C1orf123

ALTERNATIVE UPACC:
Q9NWV4

BACKGROUND:
CXXC motif containing zinc binding protein, known alternatively as UPF0587 protein C1orf123, plays a critical role in the cellular machinery. The presence of a CXXC motif, which binds zinc, indicates its importance in biochemical pathways, possibly including DNA repair and transcriptional regulation. Despite the lack of detailed information on its specific functions, the protein's unique features make it a subject of intense research interest.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of the CXXC motif containing zinc binding protein is crucial for identifying new therapeutic avenues. As research unfolds, the protein's role in cellular health and disease could provide valuable insights, leading to the development of innovative treatments for various conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.